Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niklas Dreher

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 8, 2023
Theranostics in HematooncologyAndreas K Buck, Sebastian E Serfling, Sabrina Kraus, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 18, 2026
Lesion-level dual-tracer PET biomarkers predict prognosis in multiple myeloma treated with CXCR4-directed radiopharmaceutical therapySong Xue, Sabrina Kraus, Johanna S Enke, et al.
Cancers|June 10, 2022
Associations between Normal Organs and Tumor Burden in Patients Imaged with Fibroblast Activation Protein Inhibitor-Directed Positron Emission TomographyAleksander Kosmala, Sebastian E Serfling, Niklas Dreher, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 19, 2024
Predictive value of C-X-C motif chemokine receptor 4-directed molecular imaging in patients with advanced adrenocortical carcinomaWiebke Schloetelburg, Philipp E Hartrampf, Aleksander Kosmala, et al.
Clinical Nuclear Medicine|December 11, 2023
C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Hematological Malignancies-Myeloablative Effects, Antilymphoma Activity, and Safety ProfileNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 29, 2026
Mass Dose Effects in FAP-Directed Imaging: Influence of Administered Dose of [<sup>68</sup>Ga]Ga-LNTH-1363S on Image QualityJohanna S Enke, Jan Baessler, Gitasha Chand, et al.
Clinical Nuclear Medicine|March 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Clinical Nuclear Medicine|May 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Theranostics|January 8, 2025
C-X-C motif chemokine receptor 4-directed PET signal in the arterial tree is not consistently linked to calcified plaque burden and cardiovascular riskAleksander Kosmala, Natalie Hasenauer, Sebastian E Serfling, et al.
Molecular Imaging and Biology|March 21, 2022
Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [<sup>68</sup>Ga]Ga-PentixaFor PET/CTSebastian E Serfling, Constantin Lapa, Niklas Dreher, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 8, 2023
Theranostics in HematooncologyAndreas K Buck, Sebastian E Serfling, Sabrina Kraus, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 18, 2026
Lesion-level dual-tracer PET biomarkers predict prognosis in multiple myeloma treated with CXCR4-directed radiopharmaceutical therapySong Xue, Sabrina Kraus, Johanna S Enke, et al.
Cancers|June 10, 2022
Associations between Normal Organs and Tumor Burden in Patients Imaged with Fibroblast Activation Protein Inhibitor-Directed Positron Emission TomographyAleksander Kosmala, Sebastian E Serfling, Niklas Dreher, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 19, 2024
Predictive value of C-X-C motif chemokine receptor 4-directed molecular imaging in patients with advanced adrenocortical carcinomaWiebke Schloetelburg, Philipp E Hartrampf, Aleksander Kosmala, et al.
Clinical Nuclear Medicine|December 11, 2023
C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Hematological Malignancies-Myeloablative Effects, Antilymphoma Activity, and Safety ProfileNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 29, 2026
Mass Dose Effects in FAP-Directed Imaging: Influence of Administered Dose of [<sup>68</sup>Ga]Ga-LNTH-1363S on Image QualityJohanna S Enke, Jan Baessler, Gitasha Chand, et al.
Clinical Nuclear Medicine|March 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Clinical Nuclear Medicine|May 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Theranostics|January 8, 2025
C-X-C motif chemokine receptor 4-directed PET signal in the arterial tree is not consistently linked to calcified plaque burden and cardiovascular riskAleksander Kosmala, Natalie Hasenauer, Sebastian E Serfling, et al.
Molecular Imaging and Biology|March 21, 2022
Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [<sup>68</sup>Ga]Ga-PentixaFor PET/CTSebastian E Serfling, Constantin Lapa, Niklas Dreher, et al.
Pageof 2